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ABSTRACT
Methotrexate continues to be one of the most
widely used systemic immunosuppressive
agents in dermatology. In addition to the
important, well-characterized adverse effects
such as hepatotoxicity and myelosuppression,
methotrexate may induce a number of rare
cutaneous adverse events including
methotrexate-induced ulceration. We present a
case of methotrexate-induced cutaneous
ulceration in a patient with chronic plaque
psoriasis occurring during long-standing
methotrexate therapy. Withdrawal of the drug
and appropriate skin care led to rapid healing of
the ulceration and the agent was later safely
reintroduced for the ongoing management of
the patient’s chronic plaque psoriasis. Review of
the literature demonstrates cases of this
important rare adverse event, primarily
occurring in patients with chronic plaque
psoriasis, induced by triggers such as
accidental overdose or introduction of an
interacting agent. Cutaneous ulceration
typically precedes other markers of toxicity.
Active treatment with folinic acid (calcium
leucovorin) may be required. Early
recognition, prompt cessation of
methotrexate, and appropriate treatment
minimizes morbidity. Dermatologists need to
be alert to the possibility of cutaneous adverse
events associated with methotrexate therapy,
aware of potential drug interactions, and
confident in the management of methotrexate
toxicity.
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INTRODUCTION
Introduced in the 1950s, methotrexate
continues to be one of the most widely used
systemic immunosuppressive agents in
dermatology [1, 2]. Whilst awareness of
important potential adverse events such as
hepatotoxicity, myelosuppression, and
pulmonary fibrosis are reflected in robust
guidelines for dosing and monitoring of
treatment [3], other adverse events including
cutaneous ulceration remain rarely reported
and poorly characterized. Cutaneous
ulceration may play a crucial role as an early
clinical sign of impending systemic toxicity [4].
Although rare, it is of primary importance that
dermatologists remain alert to cutaneous
indicators of methotrexate toxicity, are aware
of risk factors that may affect drug metabolism
and are confident in the management of
methotrexate overdose.
We present a case of methotrexate toxicity
manifesting with cutaneous ulceration and
review the literature, highlighting practice
points relevant to dermatology.
METHOTREXATE
Uses
Methotrexate is licensed for the treatment of
severe psoriasis, psoriatic arthritis, rheumatoid
arthritis, and a number of malignancies,
including: childhood acute lymphoblastic
leukemia, lymphoproliferative disorders,
choriocarcinoma, and various solid organ
tumors. In addition, methotrexate is an
abortifacient used in early and ectopic
pregnancy and is used off-license in a host of
dermatological conditions including atopic
eczema [5, 6] and bullous pemphigoid [1], as
well as non-dermatological conditions,
including: Crohn’s disease, systemic lupus
erythematosus, and myositis.
Methotrexate can be used as monotherapy or
in combination with other agents including
biologic therapies [7, 8]. Combination therapy
with methotrexate and infliximab has been
reported for the treatment of SAPHO
syndrome (synovitis, acne, pustulosis,
hyperostosis, and osteitis) [9], pityriasis rubra
pilaris [10], recalcitrant chronic plaque psoriasis
[11], and erythrodermic psoriasis [12]. For the
treatment of chronic plaque psoriasis,
combination therapy of etanercept with
methotrexate led to improved disease control
in a randomized, double-blinded,
placebo-controlled clinical trial [13] as well as
in reporting by individual centers [14].
Combination therapy of infliximab with
methotrexate led to dose reduction of
infliximab when compared with combinations
of infliximab and azathioprine [15], increased
dosing intervals [12], and appears to be well
tolerated when compared with methotrexate
monotherapy [16].
It is postulated that the addition of
methotrexate to biologic therapy may allow
the maintenance of therapeutic benefit through
the reduction of formation of anti-infliximab
autoantibodies [11]. While this has not been
conclusively demonstrated in dermatology
patients [17], evidence in rheumatology
cohorts suggests that addition of
immunosuppressive drugs to biologic therapy
does reduce the induction of anti-tumor
necrosis factor antibodies [17].
Mechanism of Action
Methotrexate may be administered orally,
subcutaneously, or intramuscularly.
Methotrexate is primarily bound to serum
albumin and excreted unchanged in the urine
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[1]. The drug enters cells via the reduced folate
carrier [18] where it is modified by the addition
of up to seven glutamates (methotrexate
polyglutamate; MTXPG1–7), catalyzed by the
enzyme folylpolyglutamate synthetase [18].
The MTXPGs (particularly longer chain
polyglutamates, i.e., MTXPG4–7) are not as
easily transported out of cells. They increase
the intracellular half-life of the drug and act on
several key enzymes, including dihydrofolate
reductase and thymidylate synthase, which are
involved in the pyrimidine synthesis essential
for DNA replication [18].
Decreased DNA synthesis in activated T cells
and keratinocytes may be one of the
mechanisms of action of the drug in psoriasis
vulgaris. However, methotrexate affects other
pathways, including the synthesis of adenosine
via inhibition of the enzyme 5-aminoimidazole-
4-carboxamide ribonucleotide transformylase.
This leads to a net increase in the release of
adenosine which acts as an anti-inflammatory
mediator [19].
There is considerable inter-individual
variation in toxicity and response to
methotrexate therapy. To date, one of the
largest and most comprehensive
pharmacogenetic studies in psoriasis evaluated
the role of single nucleotide polymorphisms
(SNPs) on treatment response to methotrexate
[20], demonstrating SNPs in the genes encoding
efflux transporter proteins are associated with
response to methotrexate. Evaluation of a
smaller cohort of patients demonstrated a
folate carrier allele to be associated with
methotrexate toxicity [21]. In rheumatoid
arthritis, the role of SNPs in genes coding for
intracellular polyglutamates has been evaluated
[22] and have been found to be associated with
efficacy of treatment while detectable red blood
cell levels of MTXPG4-7 have been shown to
predict clinical response [23, 24].
Pharmacogenomics may yet play a greater role
in the prediction of efficacy and toxicity of
methotrexate, with identification of genetic
markers for pre-treatment testing [25].
However, at present markers have only been
applied in small cohorts with limited
reproducibility in daily practice [26].
Toxicity of Methotrexate
In dermatology, typical starting doses of oral
methotrexate range from 5 to 15 mg weekly,
escalating every 2–4 weeks to a maximum of
around 25 mg weekly [27]. Risk of toxicity with
low-dose methotrexate treatment is felt to be
low with no evidence of increased
carcinogenicity within the dermatology
population [28]. Providing monitoring remains
satisfactory, there is no defined maximum
duration of treatment with many patients
remaining on the drug for long periods of
10–15 years [27].
Concomitant folic acid supplementation
alongside methotrexate has been shown to
reduce the incidence of gastrointestinal side
effects, liver dysfunction, and improve
continuance of treatment [29]. Higher
supplementation regimens have been posited
to reduce the efficacy of methotrexate [30, 31],
but a minimum dose of 5 mg weekly (given on
any day except that of methotrexate dosing) is
recommended [3].
Robust guidelines exist for the screening and
monitoring of patients on methotrexate for
dermatological and rheumatological
indications [3, 32]. Well-recognized side effects
include: nausea/vomiting, folic acid deficiency,
myelosuppression, hepatotoxicity (both as an
acute transaminitis and as chronic fibrosis/
cirrhosis), and pulmonary toxicity. Of these,
bone marrow toxicity can occur after long-term
treatment, but also at low doses at the initiation
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of therapy. A first dose of no more than 5 mg
with repeat full blood count prior to the second
dose is recommended in treatment naı¨ve
patients [3, 32].
Risk of hepatotoxicity is increased by
concurrent alcohol consumption, obesity,
hepatitis, diabetes mellitus, and cumulative
doses of more than 3 g of methotrexate [32].
Monitoring for liver toxicity may include
regular serum liver function testing, serial
measurement of procollagen III peptide, liver
biopsy, and/or transient elastography scanning
[33], although robust evidence to support the
utility of one or more potential biomarkers of
liver toxicity is lacking.
A key cause of toxicity is concurrent
treatment with interacting agents that
decrease protein binding or reduce renal
clearance. Some interactions (e.g., for
proton-pump inhibitors) have been reported
mainly during high-dose methotrexate
regimens [34] while others [such as
trimethoprim, non-steroidal anti-inflammatory
drugs (NSAIDs), and salicylates] have also been
reported in patients on low-dose methotrexate
[35]. Patients and physicians should be alert to
possible interactions and regularly review
additional medication use.
A number of cutaneous adverse events have
also been described, including: mucositis [36],
erythema multiforme [37], Stevens–Johnson
syndrome [38], toxic epidermal necrolysis [39,
40], photosensitivity [41], ‘recall reactions’ of
previous photodermatoses [42], exfoliative
dermatitis [43, 44], and ulceration/skin
necrosis [4]. Of these, mucositis and
photosensitivity are usually dose-related and
more commonly associated with high-dose
regimens used in chemotherapy than in
low-dose therapy used in dermatology [36, 42].
Erythema multiforme, Stevens–Johnson
syndrome, and toxic epidermal necrolysis are
idiosyncratic immune reactions where the full
mechanism is not yet understood. Drug
interactions and genetic predisposition are felt
to influence the risk of development of severe
adverse drug reactions, but are not present in all
cases [45].
CASE REPORT
We report an 83-year-old female with long-
standing severe chronic plaque psoriasis who
requested urgent assessment with a 3-week
history of oral ulceration and a 2-week history
of a flare of her psoriasis.
She had been established on methotrexate
therapy for more than 10 years. During the
course of the therapy, her dose had gradually
escalated to 25 mg once weekly. Folic acid
(5 mg) was taken once weekly on a separate
day. Her cumulative dose of methotrexate was
more than 7 g.
The patient suffered comorbidities,
including hypertension and congestive cardiac
failure. Prior to this presentation, she required
hospitalization for the treatment of cardiac
failure. Treatment comprised an increase in
the dose of her furosemide. Her other
medications were isosorbide mononitrate,
lisinopril, Adcal-D3, and quinine sulfate. No
new medications were instituted.
On attendance the patient was systemically
well and afebrile. Clinically she had oral
erosions to the buccal mucosa (Fig. 1) and
large, painful, inflamed, and ulcerated psoriatic
plaques each with a prominent tender
erythematous weepy inflamed edge (Fig. 2).
Routine bloods demonstrated a low platelet
count of 109 (normal range 150–400 9 109/L).
Renal function was normal and methotrexate
level measured at the time of admission was
undetectable.
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Skin biopsy taken from the edge of an
inflamed plaque on the trunk demonstrated
attenuation of relatively atrophic epidermis
with overlying parakeratotic scale and
apoptotic keratinocytes (Figs. 3, 4).
A diagnosis of methotrexate toxicity was
made; the drug was discontinued and topical
therapy commenced. Symptoms and signs
resolved within 2 weeks following withdrawal
of methotrexate. Treatment was reintroduced at
a lower dose of 10 mg of methotrexate weekly
with concomitant folic acid supplementation
(5 mg daily for 6 days of the week, omitted on
day of methotrexate dose) with no adverse
effects.
Informed consent was obtained from the
patient for being included in the study and for




Ulceration of the skin was well-recognized with
aminopterin [46], the precursor to
methotrexate, and was also reported shortly
after the introduction of the methotrexate as a
treatment for psoriasis [47]. It has been at the
onset of treatment [48], during long-term
Fig. 1 Oral erosions
Fig. 2 Large painful ulcerated plaques of psoriasis
Fig. 3 Histology from skin biopsy taken from the edge of
an inﬂamed plaque on the trunk
Fig. 4 Histology from skin biopsy taken from the edge of
an inﬂamed plaque on the trunk
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methotrexate therapy [49], and as a presenting
feature of accidental overdose [50].
The exact incidence of methotrexate-induced
skin ulceration is difficult to assess, but appears
to be rare. Roenigk et al. [47] noted ulceration in
6 of 204 patients treated with methotrexate,
while Lawrence and Dahl [4] reported seven
patients who had presented over the preceding
17-year period, but do not indicate what
proportion of cases this represented.
In 1996, a literature review by Pearce and
Wilson [51] identified 47 cases of
methotrexate-induced skin ulceration reported
between 1951 and 1967, and a further 17 cases
(including two of their own patients and those
by Roenigk et al. [47] and Lawrence and Dahl
[4]) between 1967 and 1996. A PubMed search
using the terms ‘‘methotrexate’’ AND
‘‘ulceration’’ identified a further 18 cases
published after 1996 (Table 1) [48–50, 52–61].
Perhaps surprisingly, most cases of
methotrexate-induced ulceration have been
reported in patients with psoriasis on low-dose
treatment rather than in those on high-dose
oncology regimens. It is postulated that that the
increased proliferation of keratinocytes within
psoriatic plaques makes them particularly
vulnerable to the effects of folate-antagonism.
However, Lawrence and Dahl [4] described two
patterns of methotrexate-induced ulceration:
type 1 as superficial ulceration of existing
psoriatic plaques and type 2 as ulceration of
non-psoriatic skin. Isolated cases of
methotrexate-induced ulceration in patients
without a history of psoriasis have been
reported including patients on low-dose
treatment for rheumatoid arthritis [52, 56] and
patients undergoing treatment for mycosis
fungoides [60].
Patients may present with isolated cutaneous
lesions or with other signs of methotrexate
toxicity including mucositis, liver dysfunction,
and/or myelosuppression. Psoriatic plaques
and/or normal skin becomes painful,
erythematous, and superficially eroded. Early
cutaneous ulceration may be mistaken for a
flare of psoriasis leading to erroneous increase
in methotrexate use by either patient [50] or
physician [4].
Diagnostic biopsy is rarely required,
however, histological features of
methotrexate-induced ulceration include
swollen keratinocytes with diminished nuclear
and cytoplasmic staining and occasional
vacuolated or dyskeratotic cells indicative of
incipient epidermal necrosis [4]. Dermal
changes include vascular dilatation and
lymphocytic infiltrates [4, 58]. Non-specific
ulceration may also be present [58].
As with other methotrexate toxicity, skin
ulceration has been described in the context of
an adverse drug interaction when new
medications are added to an existing
methotrexate regimen [62]. Examples include;
trimethoprim, amiodarone [63], furosemide
[63], penicillin [63], and NSAIDs [51].
Additional risk factors include renal
impairment and diabetes mellitus [50].
Treatment of Methotrexate Toxicity
Folate supplementation during treatment has
been shown to reduce methotrexate toxicity [31]
and improve compliance with treatment. There
is considerable variation in the prescription of
folic acid, however, a minimum of 5 mg weekly
(to be taken the day after methotrexate therapy)
is recommended for UK practice [3].
In cases of ulceration, withdrawal of
methotrexate supported by skin-directed
therapy usually leads to rapid improvement in
ulceration with many patients showing signs of
healing within a few days; however, in isolated
cases ulceration persists for years [4].
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Folinic acid (calcium leucovorin) is used for
treatment of methotrexate overdose including
ulceration [50, 55]. This treatment should be
administered as soon as possible after exposure
to methotrexate in 20 mg doses (or 10 mg/m2)
intravenously or intramuscularly, every 6 h
until serum methotrexate concentration falls
below 10-8 M (assessed every 12–24 h) or until
the total dose of folinic acid is at least equal to
the dose of methotrexate [32].
In patients with impaired renal function
receiving high-dose methotrexate for cancer
therapy who develop toxicity, glucarpidase has
been used to hydrolyze methotrexate aiding
clearance [64]. Glucarpidase is a recombinant
bacterial enzyme and received Food and Drug
Administration approval in 2012 [65]. It also has
some limited application in cases of intrathecal
methotrexate toxicity [65]. As yet there are no
reports of this agent used within the
dermatology population, however, there might
be applications in cases of acute overdose.
CONCLUSION
Our case presented with typical manifestations
of methotrexate-induced ulceration on a
background of considerable, but previously
well-tolerated, methotrexate use. Early
recognition of cutaneous findings as a marker
of methotrexate toxicity in the reported case
allowed prompt cessation of the drug avoiding
serious morbidity.
Methotrexate is a well-established element of
the dermatology therapeutic arsenal governed
by robust guidelines [32] for introduction and
monitoring which aim to minimize patient risk.
Pharmacogenomic evaluation of methotrexate
may allow for future pre-treatment testing for
risk of efficacy and toxicity. It is vital that
dermatologists are confident in the recognition
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non-cutaneous manifestations of methotrexate
toxicity in their own patients and those of other
specialties.
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